Zeren GAO,Steven D. Levin,Janine M. Bilsborough,James W. West,Cameron S. Brandt,Eric M. Chadwick
申请号：
US15973000
公开号：
US20180251556A1
申请日:
2018.05.07
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
